Detalles de la búsqueda
1.
Mutant B2M-HLA-E and B2M-HLA-G fusion proteins protects universal chimeric antigen receptor-modified T cells from allogeneic NK cell-mediated lysis.
Eur J Immunol
; 51(10): 2513-2521, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34323289
2.
Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma.
Blood
; 136(14): 1632-1644, 2020 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32556247
3.
Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial.
Cytotherapy
; 22(10): 573-580, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32527643
4.
Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy.
Gene Ther
; 25(3): 198-204, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29599530
5.
Restoration of CD3+CD56+ cell level improves skin lesions in severe psoriasis: A pilot clinical study of adoptive immunotherapy for patients with psoriasis using autologous cytokine-induced killer cells.
Cytotherapy
; 20(9): 1155-1163, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30100374
6.
Staphylococcus enterotoxin B-induced T cells can efficaciously protect against type 1 diabetes in non-obese diabetic mice.
Cent Eur J Immunol
; 40(3): 292-9, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26648772
7.
Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells.
Clin Immunol
; 155(2): 160-75, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25444722
8.
Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo.
Clin Immunol
; 149(1): 156-68, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23994769
9.
Characteristics of premanufacture CD8+T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma.
Signal Transduct Target Ther
; 8(1): 409, 2023 10 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37875502
10.
Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial.
Leukemia
; 36(1): 189-196, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34272481
11.
Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies.
Signal Transduct Target Ther
; 7(1): 98, 2022 04 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35370290
12.
CD58 loss in tumor cells confers functional impairment of CAR T cells.
Blood Adv
; 6(22): 5844-5856, 2022 11 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-35728062
13.
Clinical development of CAR T cell therapy in China: 2020 update.
Cell Mol Immunol
; 18(4): 792-804, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32999455
14.
Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming.
Nat Commun
; 12(1): 409, 2021 01 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-33462245
15.
Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial.
Oncoimmunology
; 9(1): 1846926, 2020 11 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-33312759
16.
Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.
J Hematol Oncol
; 13(1): 53, 2020 05 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-32423426
17.
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.
J Hematol Oncol
; 13(1): 30, 2020 04 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32245502
18.
PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity.
J Immunother Cancer
; 7(1): 209, 2019 08 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31391096
19.
Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation.
J Hematol Oncol
; 12(1): 57, 2019 06 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31182121
20.
Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment.
Protein Cell
; 9(6): 516-526, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28290053